Anti-HIF-1 alpha antibody [BL-124-3F7] - BSA free,Abcam,AB272040

ab272040 is the BSA-free version of ab243860 . REACH authorisation Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances. It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses. This product is sold under License from Bethyl Laboratories, Inc.

Host

Rabbit

Reactivity

Human

Application

WB, ICC, IHC-P, ChIP-seq, IP

Platform ID

BAB517829467

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-HIF-1 alpha antibody [BL-124-3F7] - BSA free
Cat. No.AB272040
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationWB, ICC, IHC-P, ChIP-seq, IP
ClonalityMonoclonal
Clone NumberBL-124-3F7
Concentration1 mg/mL Batch dependent concentration
ImmunogenRecombinant Fragment Protein within Human HIF1A aa 400 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 8.2 Preservative: 0.09% Sodium azide Constituents: 98% Borate buffered saline
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data The protein expressed by the gene HIF1A functions as a master transcriptional regulator of the adaptive response to hypoxia, activating the transcription of over 40 genes under hypoxic conditions, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and others. These genes' protein products enhance oxygen delivery or facilitate metabolic adaptation to hypoxia. HIF1A is crucial for embryonic vascularization, tumor angiogenesis, and ischemic disease pathophysiology. Its activation requires transcriptional coactivators like CREBBP and EP300, with activity enhanced by interactions with NCOA1 and/or NCOA2. Interaction with redox regulatory protein APEX1 activates CTAD and enhances activation by NCOA1 and CREBBP. Additionally, HIF1A is involved in axonal distribution and mitochondrial transport in neurons during hypoxia. In the context of microbial infection, specifically human coronavirus SARS-CoV-2, HIF1A is necessary for glycolysis induction in monocytes, leading to a proinflammatory state, inducing expression of ACE2, cytokines, and promoting virus replication and monocyte inflammatory response. This supplementary information is collated from multiple sources and compiled automatically. See full target information HIF1A

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.